GUGGENHIME ANDREW 4
4 · Vaxcyte, Inc. · Filed Feb 19, 2025
Insider Transaction Report
Form 4
Vaxcyte, Inc.PCVX
GUGGENHIME ANDREW
PRESIDENT AND CFO
Transactions
- Exercise/Conversion
Common Stock
2025-02-18$5.35/sh+8,000$42,800→ 117,491 total - Sale
Common Stock
2025-02-18$83.64/sh−6,182$517,056→ 111,309 total - Sale
Common Stock
2025-02-18$84.58/sh−1,818$153,766→ 109,491 total - Exercise/Conversion
Stock Option (right to buy)
2025-02-18−8,000→ 246,827 totalExercise: $5.35Exp: 2030-05-11→ Common Stock (8,000 underlying)
Footnotes (4)
- [F1]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted May 17, 2024.
- [F2]The price reported is a weighted-average price. The shares were sold at prices ranging from $83.17 to $84.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The price reported is a weighted-average price. The shares were sold at prices ranging from $84.125 to $84.985. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]Option is fully vested and exercisable